Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

Presentation

Prevalence, Management, and Long-term (6-Year) Outcomes of A-fib Among Patients Receiving DES

May 23, 2017

Presentation PCI Outcomes 2014

Atrial Fibrillation and PCI: Antiplatelet Therapy Recommendations

Presenter: Christopher Granger

March 28, 2014

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Presenter: B. A. Steinberg

July 24, 2013

Presentation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Presenter: Greg C. Flaker

October 09, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

Presentation

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Presenter: Hans-Christoph Diener

March 08, 2012

Advertisement

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Prevalence, Management, and Long-term (6-Year) Outcomes of A-fib Among Patients Receiving DES

Atrial Fibrillation and PCI: Antiplatelet Therapy Recommendations

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content